Actively Recruiting

Phase 4
Age: 18Years +
MALE
NCT06099093

Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan

Led by Brigham and Women's Hospital · Updated on 2026-01-29

30

Participants Needed

2

Research Sites

139 weeks

Total Duration

On this page

Sponsors

B

Brigham and Women's Hospital

Lead Sponsor

P

Progenics Pharmaceuticals, Inc.

Collaborating Sponsor

AI-Summary

What this Trial Is About

The purpose of this research study is to see how well an imaging test, called 18FDCFPyL prostate specific membrane antigen (PSMA) positron emission tomography (PET), can show the extent of prostate cancer when comparing to 68Ga-PSMA-11 PET/CT (another type of diagnostic scan for prostate cancer).

CONDITIONS

Official Title

Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan

Who Can Participate

Age: 18Years +
MALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Histologically or cytologically confirmed prostate cancer
  • Age 18 years or older
  • Planned for standard-of-care 177Lu-Vipivotide Tetraxetan therapy after the 18F-DCFPyL PSMA-PET
  • At least 1 PSMA-avid lesion on 68Ga-PSMA-11 PSMA-PET performed within 120 days prior to study entry
  • Ability and willingness to comply with study procedures
  • Prior or concurrent malignancy allowed if it does not interfere with safety or efficacy assessment
  • Agreement to use adequate contraception prior to study entry and for 24 hours after the PSMA-PET scan
  • Ability to understand and willingness to sign informed consent
Not Eligible

You will not qualify if you...

  • Uncontrolled illness including active infection, symptomatic heart failure, unstable angina, or cardiac arrhythmia
  • Contraindications to PET/CT such as severe claustrophobia
  • History of allergic reactions to compounds similar to 18F-DCFPyL
  • Any condition that may confound study results or increase risk or burden to participation according to investigators

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Dana Farber Cancer Institute

Boston, Massachusetts, United States, 02115

Actively Recruiting

2

Brigham and Womens Hospital

Boston, Massachusetts, United States, 02215

Actively Recruiting

Loading map...

Research Team

H

Heather Jacene, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

DIAGNOSTIC

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here